The 100th Article Redux: What Has Changed Since the Last Milestone

One hundred articles ago—in a different series, a different moment—I reflected on what I'd learned from a sustained engagement with the nicotine landscape. The themes then were the gap between evidence and policy, the polarization of the debate, the neglect of marginalized populations, and the need for risk-proportionate regulation. Another hundred articles later, those themes remain central—but they've been deepened, complicated, and in some cases transformed by the evidence and the arguments that have accumulated since. What's changed? The evidence has advanced. The policy battles have intensified. The institutions have hardened their positions. And the fundamental tension—between those who see harm reduction as a public health breakthrough and those who see it as an industry trap—remains unresolved. This milestone reflection revisits the themes from the first 100 articles and asks: what's new?

The evidence on non-combustible products has continued to accumulate, and the direction is consistently toward reduced risk. The biomarker studies have expanded: more populations, longer follow-up, more comprehensive panels. The pattern is consistently that switching from smoking to vaping or pouches produces substantial reductions in biomarkers of exposure to the toxicants that cause smoking-related disease. The real-world epidemiological evidence is still immature—the long-term studies that will definitively answer the cancer and respiratory disease questions won't report for years—but the absence of an emerging disease signal in the longest-duration vapers and snus users is increasingly reassuring. The evidence hasn't resolved the debate—the precautionary camp can still legitimately point to the absence of long-term data—but the weight of the available evidence has shifted further toward harm reduction. The question is whether the institutions that oppose harm reduction will acknowledge that shift.

The policy battles have intensified along the fault lines that were visible in the first 100 articles. The UK has deepened its commitment to harm reduction. Australia has deepened its commitment to precaution. The United States remains fragmented and inconsistent. The WHO FCTC COP remains captured by the precautionary coalition. The industry continues its dual strategy: promoting 'smoke-free' products in high-income markets while expanding cigarette sales in LMICs. The pattern that was visible a hundred articles ago has become more pronounced: the global nicotine policy landscape is diverging, not converging, and the divergence is producing a natural experiment whose results will take years to emerge. The countries that have embraced harm reduction are betting that the evidence of reduced risk will translate into reduced mortality. The countries that have rejected it are betting that the precautionary approach will prevent a new epidemic of nicotine addiction. Both bets are reasonable. Neither has been resolved by the evidence that's accumulated in the interval.

The institutional dynamics have hardened. The precautionary coalition, dominant in the WHO, the major U.S. health agencies, and most of the global tobacco control infrastructure, has not been persuaded by the accumulating evidence. The institutional resistance to harm reduction—rooted in the history of industry deception, the commitment to the abstinence framework, and the structural incentives of funding and career advancement—is as strong as it was a hundred articles ago. The harm-reduction community, concentrated in the UK, New Zealand, Canada, and a network of independent researchers, has not persuaded the mainstream. The debate has become more entrenched, not less—a dynamic that's characteristic of scientific controversies that are sustained by institutional commitments rather than evidentiary uncertainty.

The most significant development since the first 100 articles is the emergence of nicotine pouches as a mass-market product category, and the accumulating evidence that they represent a genuine harm-reduction opportunity for smokers who don't find vaping acceptable. Pouches have reconfigured the harm-reduction landscape: they're simpler than vaping (no device, no learning curve), more discreet, and free of the inhalation concerns that make vaping controversial. The pouch phenomenon has shifted the terms of the debate in ways that are still unfolding. For the precautionary camp, pouches represent a new threat—a product that normalizes nicotine use in formats that are invisible to parents and teachers. For the harm-reduction camp, pouches represent a breakthrough—a product that eliminates inhalation entirely while providing satisfying nicotine delivery. The evidence isn't mature enough to resolve the debate, but the direction is toward reduced risk compared to both smoking and vaping.

The most important thing that hasn't changed is the mortality. Seven million people continue to die annually from smoking-related diseases. A billion people continue to smoke. The tobacco industry continues to market combustible cigarettes aggressively in LMICs. The interventions that could dramatically reduce this mortality—risk-proportionate regulation, honest communication, accessible reduced-risk products—remain inadequately implemented. The gap between what we know and what we do remains the central tragedy of the nicotine epidemic. Another hundred articles haven't changed that gap. They've documented it, analyzed it, and advocated for closing it. But the gap persists—not because the evidence is insufficient, but because the political will to act on the evidence is insufficient.

The work continues. The evidence continues to accumulate. The arguments continue to evolve. The nicotine landscape continues to transform. Another hundred articles from now, the landscape will be different—the products, the policies, the evidence, the debates. But the central question will remain the same: how do we minimize the death and disease caused by nicotine, using the best available evidence, in a world where the institutions that should be implementing that evidence are part of the conflict? The first hundred articles asked that question. The second hundred articles deepened it. The third hundred—if there is a third hundred—will continue the inquiry. The work is not finished. The story is not complete. The next chapter is waiting to be written.